| Dopamine agonists and risk: impulse control disorders in Parkinson's; disease V Voon, J Gao, C Brezing, M Symmonds, V Ekanayake, H Fernandez, ... Brain 134 (5), 1438-1446, 2011 | 255 | 2011 |
| CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis JJ Gao, J Cheng, E Bloomquist, J Sanchez, SB Wedam, H Singh, ... The Lancet Oncology 21 (2), 250-260, 2020 | 229 | 2020 |
| Luminal a breast cancer and molecular assays: a review JJ Gao, SM Swain The oncologist 23 (5), 556-565, 2018 | 214 | 2018 |
| FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer S Arora, S Balasubramaniam, H Zhang, T Berman, P Narayan, D Suzman, ... The oncologist 26 (1), e164-e172, 2021 | 145 | 2021 |
| FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1 P Narayan, S Wahby, JJ Gao, L Amiri-Kordestani, A Ibrahim, E Bloomquist, ... Clinical cancer research 26 (10), 2284-2289, 2020 | 122 | 2020 |
| FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer P Narayan, TM Prowell, JJ Gao, LL Fernandes, E Li, X Jiang, J Qiu, J Fan, ... Clinical Cancer Research 27 (7), 1842-1849, 2021 | 107 | 2021 |
| Outcomes of older women with hormone receptor–positive, human epidermal growth factor receptor–negative metastatic breast cancer treated with a CDK4/6 inhibitor and an … LJ Howie, H Singh, E Bloomquist, S Wedam, L Amiri-Kordestani, S Tang, ... Journal of Clinical Oncology 37 (36), 3475-3483, 2019 | 68 | 2019 |
| Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab SM Swain, A Schneeweiss, L Gianni, JJ Gao, A Stein, M Waldron-Lynch, ... Annals of Oncology 28 (4), 761-768, 2017 | 41 | 2017 |
| US FDA drug approvals for breast cancer: A decade in review S Arora, P Narayan, CL Osgood, S Wedam, TM Prowell, JJ Gao, M Shah, ... Clinical Cancer Research 28 (6), 1072-1086, 2022 | 39 | 2022 |
| Preparing for survivorship: quality of life in breast cancer survivors J Gao, DS Dizon The Journal of Sexual Medicine 10 (Supplement_1), 16-20, 2013 | 35 | 2013 |
| FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase–zzxf injection for subcutaneous use in patients with HER2-positive breast cancer JJ Gao, CL Osgood, Y Gong, H Zhang, EW Bloomquist, X Jiang, J Qiu, ... Clinical Cancer Research 27 (8), 2126-2129, 2021 | 28 | 2021 |
| Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus … JJ Gao, J Cheng, TM Prowell, E Bloomquist, S Tang, SB Wedam, ... The Lancet Oncology 22 (11), 1573-1581, 2021 | 24 | 2021 |
| HALT-D: a phase II evaluation of crofelemer for the prevention and prophylaxis of diarrhea in patients with breast cancer on pertuzumab-based regimens JJ Gao, M Tan, PR Pohlmann, SM Swain Clinical breast cancer 17 (1), 76-78, 2017 | 24 | 2017 |
| Pertuzumab for the treatment of breast cancer: a safety review J Gao, SM Swain Expert opinion on drug safety 15 (6), 853-863, 2016 | 24 | 2016 |
| US Food and Drug Administration: initial experience with the real-time oncology review program RA de Claro, JJ Gao, T Kim, PG Kluetz, MR Theoret, JA Beaver, R Pazdur Clinical Cancer Research 27 (1), 11-14, 2021 | 20 | 2021 |
| US FDA drug approvals for gynecological malignancies: a decade in review S Arora, P Narayan, G Ison, T Berman, DL Suzman, S Wedam, ... Clinical Cancer Research 28 (6), 1058-1071, 2022 | 13 | 2022 |
| Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A US Food and Drug Administration pooled analysis. JJ Gao, J Cheng, E Bloomquist, R Schroeder, L Amiri-Kordestani, ... Journal of Clinical Oncology 36 (15_suppl), 1024-1024, 2018 | 12 | 2018 |
| The role of social novelty in risk seeking and exploratory behavior: Implications for addictions S Mitchell, J Gao, M Hallett, V Voon PLoS one 11 (7), e0158947, 2016 | 11 | 2016 |
| Patient‐friendly language to facilitate treatment choice for patients with cancer J Kim, J Gao, L Amiri‐Kordestani, JA Beaver, P Kluetz The Oncologist 24 (8), 1011-1012, 2019 | 7 | 2019 |
| FDA oncology center of excellence during COVID-19—working for patients with cancer JJ Gao, R Pazdur JAMA oncology 7 (3), 351-352, 2021 | 6 | 2021 |
